Middle East age related macular degeneration market report size, share, growth drivers, trends, opportunities & forecast 2025–2030

Middle East Age Related Macular Degeneration Market Overview

• The Middle East Age Related Macular Degeneration Market is valued at USD 1.1 billion, based on a five-year historical analysis. This growth is primarily driven by the increasing prevalence of age-related eye diseases, a rapidly expanding geriatric population, and advancements in treatment options such as anti-VEGF therapies and improved diagnostic imaging. The market is also supported by heightened awareness about eye health and the introduction of innovative therapies that enhance patient outcomes .
• Key players in this market include countries such as Saudi Arabia, the United Arab Emirates, and Israel, which lead due to their advanced healthcare infrastructure, high healthcare expenditure, and a significant number of ophthalmology specialists. These nations are also investing in research and development to improve treatment modalities, further strengthening their leadership in the market .
• In 2023, the Saudi Arabian government implemented the "National Eye Health Strategic Plan 2023–2027" issued by the Ministry of Health, Saudi Arabia. This binding instrument aims to reduce the incidence of age-related macular degeneration through initiatives such as funding public awareness campaigns, subsidizing advanced treatments, and enhancing early diagnosis and management of the disease. The strategy mandates improved access to ophthalmic care, integration of AMD screening in primary healthcare, and compliance with national clinical guidelines for AMD management .

Middle East Age Related Macular Degeneration Market Segmentation

By Type:The market is segmented into Dry AMD, Wet AMD, Geographic Atrophy, and Others. Among these, Wet AMD remains the most prevalent due to its severe impact on vision and the increasing number of patients seeking treatment. The growing awareness of available therapies and the effectiveness of anti-VEGF agents have significantly contributed to the expansion of this segment .

By End-User:The market is categorized into Hospitals, Eye Clinics, Home Healthcare, and Others. Hospitals are the leading end-user segment, primarily due to their comprehensive facilities and access to advanced diagnostic and treatment technologies. The increasing number of specialized eye care hospitals and the trend towards outpatient procedures are driving growth in this segment .

Middle East Age Related Macular Degeneration Market Competitive Landscape

The Middle East Age Related Macular Degeneration Market is characterized by a dynamic mix of regional and international players. Leading participants such as Novartis AG, Regeneron Pharmaceuticals, Inc., Roche Holding AG, Bayer AG, Allergan plc (an AbbVie company), Santen Pharmaceutical Co., Ltd., Apellis Pharmaceuticals, Inc., Carl Zeiss Meditec AG, Alcon Inc., Bausch + Lomb Corporation, Hoya Corporation, EssilorLuxottica SA, Topcon Corporation, Nidek Co., Ltd., Moorfields Eye Hospital NHS Foundation Trust contribute to innovation, geographic expansion, and service delivery in this space.

Middle East Age Related Macular Degeneration Market Industry Analysis

Growth Drivers

• Increasing Prevalence of Age-Related Eye Diseases:The Middle East is witnessing a significant rise in age-related eye diseases, with projections indicating that by future, approximately 2.5 million individuals will be affected by age-related macular degeneration (AMD). This increase is attributed to the aging population, with the number of people aged 65 and older expected to reach 12 million by future, according to the World Bank. Such demographic shifts are driving demand for AMD treatments and diagnostic services.
• Advancements in Diagnostic Technologies:The region is experiencing rapid advancements in diagnostic technologies, with investments in innovative imaging techniques such as optical coherence tomography (OCT). In future, the market for these technologies is projected to exceed $500 million, driven by their ability to provide early detection and improved patient outcomes. Enhanced diagnostic capabilities are crucial for timely intervention, thereby increasing the demand for AMD-related healthcare services across the Middle East.
• Rising Awareness About Eye Health:Public awareness campaigns regarding eye health are gaining momentum in the Middle East, with government initiatives and NGOs promoting regular eye check-ups. In future, it is estimated that over 60% of the population will have participated in eye health awareness programs, significantly increasing the early detection of AMD. This heightened awareness is expected to lead to a surge in patient consultations and treatment uptake, further propelling market growth.

Market Challenges

• High Treatment Costs:The cost of AMD treatments remains a significant barrier in the Middle East, with average annual treatment expenses reaching approximately $15,000 per patient. This high financial burden limits access to necessary therapies for many individuals, particularly in lower-income populations. As healthcare systems strive to provide affordable care, addressing these costs will be essential for improving patient access and outcomes in AMD management.
• Limited Access to Specialized Care:Access to specialized eye care services is uneven across the Middle East, with rural areas facing significant shortages of ophthalmologists. In future, it is estimated that there will be only 1.5 ophthalmologists per 100,000 people in these regions, compared to 5 in urban centers. This disparity creates challenges in timely diagnosis and treatment of AMD, hindering overall market growth and patient care quality.

Middle East Age Related Macular Degeneration Market Future Outlook

The future of the Middle East Age Related Macular Degeneration market appears promising, driven by technological advancements and increasing healthcare investments. By future, the integration of artificial intelligence in diagnostics is expected to enhance accuracy and efficiency, while telemedicine will expand access to specialized care. Additionally, the growing emphasis on preventive eye care will likely lead to earlier interventions, improving patient outcomes and reducing long-term healthcare costs associated with AMD.

Market Opportunities

• Growth in Telemedicine for Eye Care:The rise of telemedicine presents a significant opportunity for AMD management, particularly in underserved areas. By future, telemedicine consultations are projected to increase by 40%, allowing patients to access specialists remotely. This shift can enhance patient engagement and adherence to treatment plans, ultimately improving health outcomes in the region.
• Development of Innovative Treatment Options:The ongoing research and development of novel therapies for AMD, including gene therapy and stem cell treatments, are set to revolutionize patient care. By future, the introduction of at least three new treatment modalities is anticipated, potentially increasing treatment efficacy and patient satisfaction. This innovation will create new market segments and attract investment in the AMD treatment landscape.